上客户端，和病友交流

点击下载

胃癌

Anthony Shields M.D., Ph.D.

外科

Karmanos cancer center

擅长疾病

临床新药咨询

通过咨询找到适合自己的药物

去咨询

专家会诊咨询

专业、及时的一对一咨询

去咨询

如果您的问题未能解决，您还可以选择：

医学顾问

: 极速问诊

2万名名医
7*24小时为您匹配

1对1

: 找专家

肿瘤专科专家
对症找医专科专治

专家介绍

2015-06-17 15:572890

· Gender

· Male

· Multidisciplinary Team(s)

· Gastrointestinal Oncology

· Department/Research Program(s)

· Department of Oncology
Molecular Imaging & Diagnostics Program

· Cancer Type(s)

· Ampullary and periampullary cancers
Anal Cancer
Appendix Cancer
Bile Duct Cancer
Cancer of unknown origin
Carcinoid Tumors
Cholangiocarcinoma
colon Cancer
Esophageal Cancer
Gall Bladder Cancer
Gastroesophageal Junction (GEJ)
Gastrointestinal Stromal Tumors (GIST)
Liver Cancer
Neuroendocrine Tumors
Pancreatic Cancer
Pancreatic Neuroendocrine Tumor (pNET)
Peritoneum and psuedomyxoma peritonii
Rectal Cancer
Small Intestine Cancer
Stomach Cancer

· Contact Info

· Email:
shieldsa@karmanos.org

来自 <http://www.karmanos.org/physicians/Anthony-Shields?Disease=238&PageIndex=0&SortDirection=1>

· Education

· Fellowship
Medical oncology Fellowship: University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington
Medical School
Harvard Medical School
Residency
Internal Medicine, University of Washington School of Medicine, Seattle, Washington
Graduate Training
Massachusetts Institute of Technology (Ph.D)

· Professional Memberships/Associations

· American Society of Clinical Oncology
American Society of Hematology
Society of Nuclear Medicine
American Association for Cancer Research
American Society for Microbiology
World Molecular Imaging Society

· Board Certifications

· American Board of Internal Medicine
National Board of Medical Examiners
American Board of Medical oncology and Hematology

· Clinical Interests

· Medical Oncology, Gastrointestinal Oncology

· Research Interests

· Gastrointestinal Oncology, Molecular Imaging to assess treatment response, Imaging Agents

· Profile

· Dr. Shields' career has been dedicated to clinical research and the care of patients with colorectal, pancreatic and other gastrointestinal cancers. His experiences in research and the clinic make him painfully aware of the need to develop new approaches in understanding and overcoming resistance to treatment for patients with GI cancer. At Karmanos Cancer Institute and Wayne University School of Medicine he leads clinical research efforts through his roles as the Associate Center Director for Clinical Sciences, Program Leader in Molecular Imaging and Diagnostics and Professor of oncology and Medicine. Dr. Shields training as a Medical oncologist provides the insight to guide studies in patients with cancer and the foresight to design trials that are appropriate. He has a broad understanding in clinical sciences with experience that spans from protocol design and development to implementation from the local to the national level. He is the sub-chair for colorectal cancer at the Southwest oncology Group (SWOG), and co-chair for a national adjuvant colon cancer study sponsored by the Cancer and Leukemia Group B (CALGB) and SWOG. He serves on the NCI colon Task Force, which is charged with overseeing clinical research studies in colorectal cancer, and has served on the NCI Investigational Drug Steering Committee. In the clinic, his work concentrates on the treatment of patients with gastrointestinal (GI) cancer and he continues to develop and lead new clinical trials for GI tumors. This includes serving as a founding faculty member of the Clinical Trials Methodology Workshop under the sponsorships of the Radiological Society of North America (RSNA) and the National Cancer Institute, which is designed to mentor new faculty. As an Associate Center Director for Clinical Sciences, and member of the Human Investigation Committee Review Board, he helps to oversee a large number of clinical studies within our Institute and comprehends the complexities and challenges of the approaches to successful evaluation of new agents. Dr. Shields clearly has a crucial role in the design of cancer clinical trials. His laboratory research focuses on the development and testing of tracers for use with positron emission tomography (PET) for the assessment of a variety of tumors (e.g. brain, lung, breast, and prostate cancers) and their response to treatment. Dr. Shields led the development of FLT {3'-deoxy-3'-fluorothymidine}; a promising tracer for tumor proliferation, which has received an IND from the FDA and is being tested in centers worldwide. He serves on the Steering Committee of the American College of Radiology (ACRIN) and the National oncology PET Registry (NOPR) and works to incorporate innovative imaging in the multicenter clinical trials. He is Senior Editor for Molecular Imaging and Biology and the Journal of Nuclear Medicine, and a reviewer for a number of journals, including the New England Journal of Medicine, Nature Medicine, and The Journal of Clinical Oncology. He has authored over 100 peer-reviewed articles and more than 20 book chapters, reviews and case reports on cancer research.

· Awards

· 2005, 2009-2013 Voted one of the Best Doctor's in America by Best Doctors Inc.
Selected by Castle Connolly Medical Ltd. as one of the region's Top Doctors
2007 Wayne State University Distinguished Faculty Fellowship Award
2005 European Association of Nuclear Medicine and Springer-Verlag Award - Best Clinical Paper
2005 Peter Valk Distinguished Clinical Scientist Award, Academy of Molecular Imaging

· Publications

· Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 307:1383-93. 2012. PMID: 22474202 Authors: Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM.
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs, 29:694-9, 2011. Epub Jan 27, 2010. PMID: 20107864. Authors: El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL.
Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience. Am J Clin Oncol. 34:135-9. 2011. PMID: 20523206 Authors: Hammad N, Heilbrun LK, Gupta S, Tageja N, Philip PA, Shields AF, Smith D, El-Rayes BF
Impact of dedicated brain PET on intended patient management in participants of the National oncologic PET Registry. Mol Imaging Biol. 13:161-5, 2011. Epub Oct 7, 2010. PMID: 2108023 Authors: Hillner BE, Siegel BA, Shields AF, Fenghai D, Gareen IF, Hanna L, Coleman RE.
Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. Invest New Drugs. 29: 1395-405, 2011. Epub Jul 6, 2010. PMID: 20607586 Authors: Lorusso P, Shields AF, Gadgeel S, Vaishampayan U, Guthrie T, Puchalski T, Xu J, Liu Q.

来自 <http://www.karmanos.org/Physicians/Details.aspx?sid=1&physician=35&Disease=238&PageIndex=0&SortDirection=1>

1. 添加医学顾问微信，扫描☟二维码

2. 备注【癌种】进病友群

扫描预约专家问诊

专家科普

【3月12日】肿瘤患者怎样避免人财两空？

483全球肿瘤医生网医学部
肿瘤临床试验患者真实采访（下）患者谈：临床试验是小白鼠吗？

591全球肿瘤医生网医学部
肿瘤临床试验患者真实采访（上）临床试验带来的希望

598全球肿瘤医生网医学部
胃癌IV期伴有肝脏及肝胃间隙淋巴结转移患者赴日就医

1333全球肿瘤医生网医学部
大肠癌伴肝转移患者赴日就医

987全球肿瘤医生网医学部
胶质母细胞瘤和髓母细胞瘤患者赴日就医

959全球肿瘤医生网医学部
肝癌患者日本国际就医案例

895全球肿瘤医生网医学部
癌症患者的新方案来了！数十位国际专家带先进技术助力国内癌症患者

1171全球肿瘤医生网医学部